News Headlines

  1. Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
    12/18/2018

    Sangamo Therapeutics, Inc., a genomics medicines company, recently announced treatment of the first patient in the Phase 1/2 clinical trial evaluating SB-FIX, an investigational in vivo genome editing therapy for patients with hemophilia B.

  2. BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab, In Patients With Gastric Cancer And In Patients With Esophageal Cancer
    12/18/2018

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patients have been enrolled in two global Phase 3 clinical trials of its investigational anti-PD-1 antibody, tislelizumab.

  3. VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
    12/17/2018

    Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.

  4. Protalix BioTherapeutics Announces The Completion Of Enrollment In The Phase III BRIDGE Clinical Trial Of Pegunigalsidase Alfa For The Treatment Of Fabry Disease
    12/17/2018

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease.

  5. Lilly To Acquire Pre-Clinical Pain Program From Hydra Biosciences
    12/14/2018

    Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes.

  6. Inspire’s Health Profiles Identifies The Insights Of Patients To Unlock Research Gaps
    12/14/2018

    Inspire, the leading healthcare social network for patients and caregivers, is offering new opportunities for academic research partners to participate in the expansion of its Health Profiles data platform.

  7. Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data And Initiates Pivotal Phase 3 Clinical Trial
    12/12/2018

    Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling, in subjects with symptomatic recurrent pericarditis.

  8. Rafael Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial (AVENGER 500) Of CPI-613 (Devimistat) In Combination With Modified FOLFIRINOX As First Line Treatment For Patients With Metastatic Pancreatic Cancer
    12/12/2018

    Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a phase 3 multicenter, open-label, randomized pivotal trial (AVENGER 500) to evaluate the efficacy and safety of its lead compound CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy in patients with metastatic adenocarcinoma of the pancreas.

  9. Aravive Biologics Initiates Phase 1b Portion Of Phase 1b/2 Clinical Trial Of AVB-S6-500 In Platinum-Resistant Recurrent Ovarian Cancer
    12/12/2018

    Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer.

  10. Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment With INB03
    12/12/2018

    INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the innate immune system, today announced that its lead drug candidate for treatment-resistant cancers, INB03™, successfully inhibited the proliferation of tumor growth in pre-clinical models of trastuzumab treatment-resistant breast cancer.